0.542
-0.02 (-3.71%)
| 前收盘价格 | 0.563 |
| 收盘价格 | 0.545 |
| 成交量 | 761,455 |
| 平均成交量 (3个月) | 1,748,679 |
| 市值 | 41,692,588 |
| 价格/销量 (P/S) | 252.22 |
| 股市价格/股市净资产 (P/B) | 4.42 |
| 52周波幅 | |
| 利润日期 | 11 Nov 2024 - 15 Nov 2024 |
| 营业利益率 (TTM) | -51,661.19% |
| 稀释每股收益 (EPS TTM) | -0.690 |
| 总债务/股东权益 (D/E MRQ) | 915.08% |
| 流动比率 (MRQ) | 0.460 |
| 营业现金流 (OCF TTM) | -30.23 M |
| 杠杆自由现金流 (LFCF TTM) | -18.18 M |
| 资产报酬率 (ROA TTM) | -92.94% |
| 股东权益报酬率 (ROE TTM) | -914.66% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Eyenovia, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.75 |
|
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 10.00% |
| 机构持股比例 | 13.73% |
| 52周波幅 | ||
| 中 | 2.00 (268.94%) | |
| 总计 | 1 保留 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 18 Nov 2024 | 2.00 (268.94%) | 保留 | 0.111 |
| 13 Nov 2024 | 12.00 (2,113.61%) | 购买 | 0.408 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合